FDA approves label changes for Sublocade (buprenorphine extended-release) including rapid initiation and alternative injection sites – Indivior
Indivior PLC announced that the FDA has approved label changes for Sublocade (buprenorphine extended-release ) including a rapid initiation protocol and alternative injection sites, marking a significant advancement… read more.